Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

ABSTRACT:

Background

The cause of death in patients with chronic kidney disease (CKD) varies with CKD severity, but variation has not been quantified.

Study design

Retrospective analysis of prospective randomized clinical trial.

Setting & participants

We analyzed 4,038 individuals with anemia and diabetic CKD from TREAT, a randomized trial comparing darbepoetin alfa and placebo.

Predictors

Baseline estimated glomerular filtration rate (eGFR) and protein-creatinine ratio (PCR).

Outcomes

Cause of death as adjudicated by a blinded committee.

Results

Median eGFR and PCR ranged from 20.6 mL/min/1.73 m(2) and 4.1 g/g in quartile 1 (Q1) to 47.0 mL/min/1.73 m(2) and 0.1 g/g in Q4 (P<0.01). Of 806 deaths, 441, 298, and 67 were due to cardiovascular (CV), non-CV, and

SUBMITTER: Charytan DM 

PROVIDER: S-EPMC4549188 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature